{"entity":{"id":"bp2201","kind":"drug","name":"BP2201","aka":[],"tldr":"BP2201 is an experimental iPS cell-derived NKT cell therapy from BrightPath Biotherapeutics, in phase 1 trials for head and neck cancer; its current status is not stated.","summary":"BP2201 is an iPS cell-derived NKT cell therapy (allogeneic) from BrightPath Biotherapeutics. Allogeneic NKT cells regenerated from iPS cells, which can kill cancer cells directly and activate other immune cells. Its furthest stage is phase 1, for head and neck cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Company page says a phase 1 in head and neck cancer showed initial safety and clinical activity; no ClinicalTrials.gov entry found. It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"BrightPath Biotherapeutics: brightpathbio.com","url":"https://www.brightpathbio.com/pipeline/bp2201.html"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BP2201","modality":"iPS cell-derived NKT cell therapy (allogeneic)","mechanism":"Allogeneic NKT cells regenerated from iPS cells, which can kill cancer cells directly and activate other immune cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bp2201/","neighbours":{"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}]}}